PDS Biotechnology regains Nasdaq bid-price compliance

PDS Biotechnology Corporation reported that it has regained compliance with the Nasdaq Capital Market’s minimum bid price rule.

Rhea-AI Filing Summary

PDS Biotechnology Corporation reported that it has regained compliance with the Nasdaq Capital Market’s minimum bid price rule. Nasdaq had previously notified the company that its common stock closed below the required $1.00 per share for 30 consecutive business days, triggering a deficiency notice. On June 2, 2026, Nasdaq informed PDS Biotechnology that the company once again meets the Minimum Bid Price Requirement and that the compliance matter is now closed.

Insights

Equity listing & capital markets analyst

Regaining Nasdaq bid-price compliance removes immediate delisting risk.

PDS Biotechnology Corporation had fallen below Nasdaq’s $1.00 minimum bid price for 30 consecutive business days, which led to a deficiency notice from the Nasdaq Listing Qualifications Department. Such notices can ultimately lead to delisting if not cured.

Nasdaq’s written confirmation on June 2, 2026 that the company now satisfies the Minimum Bid Price Requirement and has closed the matter means the stock currently retains its Nasdaq Capital Market listing under that rule. Actual long-term impact will depend on the company’s ability to maintain compliance as trading continues.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Minimum bid price threshold: $1.00 per share Deficiency notice date: February 25, 2026 Compliance regained date: June 2, 2026

3 metrics

Minimum bid price threshold $1.00 per share Nasdaq Listing Rule 5550(a)(2) requirement

Deficiency notice date February 25, 2026 Date Nasdaq notified PDS Biotechnology of non-compliance

Compliance regained date June 2, 2026 Date Nasdaq confirmed PDS Biotechnology met bid price rule

Key Terms

Minimum Bid Price Requirement, Nasdaq Capital Market, Nasdaq Listing Qualifications Department

3 terms

Minimum Bid Price Requirement regulatory

"has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”)."

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

Nasdaq Capital Market regulatory

"the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2)"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

Nasdaq Listing Qualifications Department regulatory

"received a deficiency letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC"

The Nasdaq Listing Qualifications Department is the team at the Nasdaq stock market that monitors whether listed companies meet the exchange’s rules for things like minimum share price, market value, timely financial reporting and governance. Its role matters to investors because its notices, warnings or enforcement actions—ranging from reminders to suspension or delisting—can sharply affect a stock’s trading, liquidity and perceived risk; think of it as the referee enforcing the marketplace’s entry and conduct rules.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did PDS Biotechnology Corporation (PDSB) announce in this 8-K?

PDS Biotechnology announced it has regained compliance with Nasdaq’s minimum bid price rule. Nasdaq confirmed the company now meets the listing requirement and has closed the prior deficiency matter related to the stock trading below the required threshold.

Why was PDS Biotechnology (PDSB) previously non-compliant with Nasdaq rules?

PDS Biotechnology became non-compliant because its common stock’s closing bid price was below $1.00 per share for 30 consecutive business days. This violated Nasdaq Listing Rule 5550(a)(2), known as the Minimum Bid Price Requirement for continued listing on the Nasdaq Capital Market.

When did PDS Biotechnology (PDSB) receive the original Nasdaq deficiency notice?

The company received the original Nasdaq deficiency letter on February 25, 2026. That letter informed PDS Biotechnology that its common stock had failed to meet the $1.00 minimum bid price for 30 consecutive business days required for continued listing on the Nasdaq Capital Market.

When did PDS Biotechnology (PDSB) regain compliance with the Nasdaq bid price rule?

PDS Biotechnology received written notice from Nasdaq on June 2, 2026 confirming it had regained compliance. Nasdaq stated that the company again meets the Minimum Bid Price Requirement and that the related compliance matter has been closed.

What is the Nasdaq Minimum Bid Price Requirement mentioned for PDSB?

The Minimum Bid Price Requirement is Nasdaq Listing Rule 5550(a)(2), which requires a minimum $1.00 per share closing bid price for a company’s common stock. PDS Biotechnology temporarily failed this standard but has since been notified that it is again in compliance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/02/2026 - 03:35 PM Learn about SEC filing dates

false0001472091NASDAQ00014720912026-06-022026-06-02

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 2, 2026

PDS BIOTECHNOLOGY CORPORATION

(Exact Name of Registrant as Specified in Charter)

Delaware	001-37568	26-4231384
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

303A College Road East, Princeton, NJ 08540

(Address of Principal Executive Offices, and Zip Code)

(800) 208-3343

Registrant’s Telephone Number, Including Area Code

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.00033 per share	PDSB	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☐ No ☐

Item 8.01 Other Events.

As previously disclosed, on February 25, 2026, PDS Biotechnology Corporation (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).

On June 2, 2026, the Company received written notice from Nasdaq informing the Company that it has regained compliance with the Minimum Bid Price Requirement and that Nasdaq has closed the matter.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PDS BIOTECHNOLOGY CORPORATION
Date: June 2, 2026	By:	/s/ Frank Bedu-Addo, Ph.D.
	Name: Frank Bedu-Addo, Ph.D.
	Title: President and Chief Executive Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 21.5 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 15.7 KB